Original Article

Serum 25-hydroxyvitamin D levels and diabetic retinopathy: a systematic meta-analysis

Fang Liang1*, Kuixiang Wang2*, Hongxia Zhang1, Jian Zhang1, Xinsheng Nie1, Zhanxiu Zhang2, Zhenfeng Shi1

Departments of ¹Endocrinology, ²Joint Orthopedics, Xingtai People's Hospital, Hebei Medical University, Xingtai 054000, Hebei Province, China. *Equal contributors.

Received November 17, 2015; Accepted September 23, 2016; Epub December 1, 2016; Published December 15, 2016

Abstract: Vitamin D is a multifunctional pro-hormone, which is suggested to have protective effects against diabetes mellitus. Several studies showed a possible association between vitamin D deficiency and diabetic retinopathy (DR) in patients with diabetes. However, the results have been inconsistent. So, a systematic meta-analysis was performed to comprehensively assess the association between serum 25-hydroxyvitamin D [25(OH)D] levels and DR in patients with diabetes. In this study, multiple databases were searched until May 2015 to identify relevant studies. The search term was "vitamin D" and "diabetic retinopathy". We identified eleven studies on association between vitamin D deficiency and DR in patients with diabetes mellitus and five studies on association between vitamin D deficiency and DR in patients with T2DM, The data were accessed by software Review manager 5.2. A total of 6851 diabetic patients and 2189 T2DM patients were finally included into the meta-analysis. Meta-analysis showed that there were obviously decreased serum 25(OH)D levels in DR patients [95% confidence interval (CI) 0.92 to 2.51, P<0.00001]. Vitamin D deficiency was also significantly associated with increased risk of DR in patients with T2DM [odds ratio (OR) 1.15, 95% CI 0.84-1.56, P<0.00001]. Meta-analysis of three studies with adjusted estimates showed that vitamin D deficiency was independently associated with increased risk of DR in patients with type 2 diabetes (OR 2.68, 95% CI 1.67-4.30, P<0.0001). We did not find evidence of publication bias. In conclusion, Vitamin D is involved in the development of DR in diabetic patients, and vitamin D deficiency is very likely to be associated with DR in type 2 diabetic patients. Further studies are needed to validate the association between vitamin D deficiency and DR.

Keywords: 25-hydroxyvitamin D, type 2 diabetes, diabetic retinopathy, meta-analysis

Introduction

Diabetic retinopathy (DR), which is among the most common diabetes complications [21, 22, 34], which affects more than 300 million individuals in the world with significant morbidity and mortality worldwide. Major risk factors for DR include a longer diabetes duration, age, smoking, poor glycemic control, and hypertension [10, 35], which have been strongly and consistently associated with DR across populations.

In parallel to the increase in the prevalence of diabetes mellitus, there has been a resurgence of vitamin D deficiency worldwide [1, 8, 25, 29], and much evidence have suggested that VDD is involved in the development of various diseases including diabetes [2, 3], cardiovascular

disease [4, 7, 23], cancer [24], and autoimmune diseases. Recent studies have shown that VD has inhibitory effects on inflammation and proliferation in endothelial cells, and angiogenesis [28, 31], which are involved in the development of DR. In addition, recent studies have also shown that Vitamin D receptor (VDR) is expressed in retina [5, 6, 9], and VD has direct inhibitory effects on the development of DR in experimental animal models. Albert et al. revealed that VD inhibits retinal neovascularization in a mouse oxygen-induced ischemic retinopathy model. Ren et al. revealed that VD has protective effects on DR by inhibiting vascular endothelial growth factor (VEGF) and transforming growth factor-b1 (TGF-b1) in the retinas of diabetic rats. In addition, some human genetic studies have shown that polymorphisms of VDR gene are associated with DR. These results

Table 1. Characteristics of observational studies on 25-hydroxyvitamin D levels and Diabetic Reti-
nopathy

Author	Year	Country	Age	Control (DM)			Case (BDR1, NPDR2, PDR3)		
				Number	Male	25(OH)D (ng/ml)	Number	Male	25(OH)D (ng/ml)
HULYA AKSOY [10]	2000	Turkey	57.3±7.37	20	12	29.8±10.50	46	23	30.9±12.48 1
									35.3±13.30 2
									29.0±14.20 3
Naoki Shimo [11]	2014	Japan	28.5±5.5	31	-	-	44	-	-
HARLEENKAUR [12]	2011	Australia	14.9±2.4	95	-	-	400	-	-
Hala Ahmadieh [13]	2013	Lebanon	59±11	105	-	-	31	-	-
R. He [14]	2014	CHINA	59.03±11.67	625	317	18.86±7.12	895	456	17.44±6.19
									15.36±4.81
Patricia A [15]	2014	American	62.7±11.1	1522	-	-	268	-	-
John F. Payne [16]	2012	Atlanta		82		24.3	41		23.6 2
									21.1 3
Barbara J [17]	2014	Africa	55.2±13	84	39	38±11.3	66	26	25.1±14.8
Shokoufeh [18]	2014	Iran	54.8±9.4	153	27	10.3±9.4	72	15	9.0±7.0
									10.1±6.8
Sarita Bajaj [19]	2014	India	52.85±8.26	104	-	23.10±6.12	54	-	19.25±7.86
Donghyun Jee [20]	2014	Korean	60.4±0.3	1738	954	18.7 (0.2)	375	204	18.3 (0.4)




Figure 1. Flow chart of literature search and study selection.

suggest a role of VD in the pathogenesis of the development of DR.

Several studies reported a high prevalence of vitamin D deficiency in DR patients with diabetes. However, subsequent studies reported inconsistent results. As small sample size may have led to a weak or non-significant associations in those studies, the aim of this metanalysis was to examine the association bet-

ween serum vitamin D and DR.

Methods

We generally followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We searched literature published in PubMed, EBSCO, and Springer database until May 2015 to identify relevant studies that assessed the association between serum 25-hydroxyvitamin D and DR. Search terms included "vitamin D" and "diabetic retinopathy".

Because there were no cohort studies, we could only select and analyze case-control and

cross-sectional study which reported serum vitamin D levels of DR patients. Two authors (F.L. and K-X. W.) extracted data independently and disagreements were resolved by discussion. Information on each study is provided in **Table 1**.

In the meta-analysis graphical representation, the area of the black square indicates the weight contributed by each study. Heterogeneity




Figure 2. Meta-analysis of DM group and T2DM group. A: DM; B: T2DM.

was estimated by I², substantial hetero-geneity exists when I² exceeds 50%. A random effect model was used if heterogeneity was observed, while the fixed-effect model was applied in the absence of heterogeneity. All analyses were performed using Review Manager 5.2 software (Cochrane Collaboration, Oxford, England). A *P* value of less than 0.05 was considered to be statistically significant.

Results

Figure 1 presents a flow chart of the study selection process. We initially identified a total of 383 articles. After screening titles and abstracts, reviews and irrelevant articles, 15 relevant articles remained for full-text evaluation. Finally 11 studies were included in our study. Characteristics of the selected studies are presented in Table 1.

Meta-analysis of 25-hydroxyvitamin D and DR

In total, 6851 participants were included in this analysis. There was significant heterogeneity among the 11 studies ($I^2 = 84\%$, P < 0.00001) and therefore a random effect model was used. The serum 250HD levels of DM group was 1.51 ng/mL [95% confidence interval (CI): 0.92-2.51, P < 0.0001] lower than in control group (**Figure 2A**).

Meta-analysis of 25-hydroxyvitamin D and DR in patient with T2DM

A total of 2189 participants were included. Again a random effects model was used because of significant heterogeneity among the 5 studies ($I^2 = 98\%$, P<0.00001). The serum 250HD levels of T2DM group were 1.15 ng/mL [95% confidence interval (CI): 0.84-1.56,

P<0.0001] lower than the control group (**Figure 2B**).

Discussion

Recently, studies have evaluated the association between VD and the risk of DR [10, 32]. However, the results remain conflicting and inconsistent, and thus a systematic review and meta-analysis of association between the VD and DR were of great value. Our meta-analysis shows that patients with DR have a lower level of serum 250HD.

If this association represents a causal link, complex mechanisms may be involved. Vitamin D affects on insulin secretion and insulin sensitivity [27]. It has immunosuppressive effect, anti-fibrotic properties and causes suppression in rennin-angiotensin system (RAS). A recent study suggested that vitamin D inhibited retinal neovascularization in a mouse model of c retinopathy and restrained endothelial cell proliferation in cell culture. Further rischaemiesearch indicated that vitamin D had a protective effect on diabetic retinopathy via the inhibition of inflammation, vascular endothelial growth factor [33] and transforming growth factor-\(\beta 1 \) (TGFβ1) expression in retinal tissues. Some study VD can inhibit the oxidative stress among DM patients with DR [36]. Data from animal models support a causal role for vitamin D deficiency in proliferative retinopathy. Vitamin D deficiency may play a role in the pathogenesis of diabetic retinopathy. Masayuki Ouchi et al. represents Vitamin D-binding protein existed in vitreous from diabetic macular edema, which may play a role in the pathogenesis.

Some clinical trials have shown beneficial effects of vitamin D receptor (VDR) on DR [30]. Furthermore, the vitamin D receptor (VDR) is present in the human retina, and polymorphisms of VDR gene are related to retinopathy in patients with type 1 diabetes [26]. Data from Taverna MJ also support the association between VDR and low risk for severe diabetic retinopathy, especially in patients with long duration. Cyganek K et al. reported that VDR gene polymorphisms did not constitute a risk factor for type 2 diabetes patients in Polish. Zhelong Liu et al. did not find any association of the three polymorphisms (Bsml, Apal and Taql) with an increased diabetic microvascular complications (DMI) risk in overall and subgroup analysis by meta-analysis. However, due to complicated interactions of environmental factors and multiple genes, the precise role of VDR gene Fokl polymorphism in DR remains elusive. Additional future studies should be performed to focus on the function of the VDR gene Fokl polymorphism.

In the present meta-analysis, there existed a significant heterogeneity among the eleven studies. The sources of heterogeneity may come from ethnicity, gender, age, and so on, which was not performed on account of lack of information in these studies.

Conclusions

In conclusion, this meta-analysis had pooled all the available data related to the 250HD and DR, and indicated that the 250HD may be an increased susceptibility to DR. Therefore, more well-designed and large sample studies are warranted to confirm this conclusion, and to fully understand the mechanism of DR. Additionally, prospective cohort studies in combination with analyses of other gene and environment factors are also necessary to explore the true effect of the 250HD on the risk of DR.

Disclosure of conflict of interest

None.

Address correspondence to: Zhenfeng Shi, Department of Endocrinology, Xingtai People's Hospital, Hebei Medical University, Xingtai 054000, Hebei Province, China. E-mail: Zhenfengshi223@163.com

References

- [1] Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ. Vitamin D Intake and Risk of Type 1 Diabetes: A Meta-Analysis of Observational Studies. Nutrients 2013; 5: 3551-3562.
- [2] Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care 2011; 34: 1081-1085.
- [3] Boucher BJ. Matrix metalloproteinase-10 and microvascular complications of type 1 diabetes: might vitamin D status be relevant?. Diabetologia 2014; 57: 1081.
- [4] Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes 2014; 5: 835-846.
- [5] Zhong X, Du Y, Lei Y, Liu N, Guo Y, Pan T. Effects of vitamin D receptor gene polymorphism and

- clinical characteristics on risk of diabetic retinopathy in Han Chinese type 2 diabetes patients. Gene 2015; 566: 212-6.
- [6] Liu Z, Liu L, Chen X, He W, Yu X. Associations study of vitamin D receptor gene polymorphisms with diabetic microvascular complications: a meta-analysis. Gene 2014; 546: 6-10.
- [7] Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ; VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis 2013; 228: 502-507.
- [8] Feng R, Li Y, Li G, Li Z, Zhang Y, Li Q, Sun C. Lower serum 25 (OH) D concentrations in type 1 diabetes: A meta-analysis. Diabetes Res Clin Pract 2015: 108: e71-5.
- [9] Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 2005; 81: 176-182.
- [10] Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1,25 Dihydroxy Vitamin D (1,25(OH) 2D3), 25Hydroxy Vitamin D (25(OH)D) and Parathormone Levels in Diabetic Retinopathy. Clin Biochem 2000; 33: 47-51.
- [11] Shimo N, Yasuda T, Kaneto H, Katakami N, Kuroda A, Sakamoto F, Takahara M, Irie Y, Horikawa K, Miyashita K, Miyatsuka T, Yoshiuchi K, Kawamori D, Sakamoto K, Matsuoka TA, Kosugi K, Shimomura I, Matsuhisa M. Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients. Diabetes Res Clin Pract 2014; 106: E41-E43.
- [12] Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, Cusumano J, Pryke A, Craig ME. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011; 34: 1400-1402.
- [13] Ahmadieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: a relation to disease control and complications. ISRN Endocrinol 2013; 2013: 641098.
- [14] He R, Shen J, Liu F, Zeng H, Li L, Yu H, Lu H, Lu F, Wu Q, Jia W. Research: complications vitamin d deficiency increases the risk of retinopathy in chinese patients with type 2 diabetes. Diabet Med 2014; 31: 1657-1664.
- [15] Patrick PA, Visintainer PF, Shi Q, Weiss IA, Brand DA. Vitamin D and Retinopathy in Adults With Diabetes Mellitus. Arch Ophthalmol 2012; 130: 756-760.
- [16] Payne JF, Ray R, Watson DG, Delille C, Rimler E, Cleveland J, Lynn MJ, Tangpricha V, Srivastava SK. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract 2012; 18: 185-93.

- [17] Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14: 179-183.
- [18] Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
- [19] Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011. Invest Ophthalmol Vis Sci 2013; 54: 6827-6833.
- [20] Mangge H, Weghuber D, Prassl R, Haara A, Schnedl W, Postolache TT, Fuchs D. The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player? Curr Vasc Pharmacol 2015; 13: 392-8.
- [21] Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014; 2: 76-89.
- [22] Payne JF, Ray R, Watson DG, Delille C, Rimler E, Cleveland J, Lynn MJ, Tangpricha V, Srivastava SK. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract 2012; 18: 185-193.
- [23] Personne V, Partouche H, Souberbielle JC. [Vitamin D insufficiency and deficiency: epidemiology, measurement, prevention and treatment]. Presse Med 2013; 42: 1334-1342.
- [24] Gyorffy B, Vásárhelyi B, Krikovszky D, Madácsy L, Tordai A, Tulassay T, Szabó A. Gender-specific association of vitamin D receptor polymorphism combinations with type 1 diabetes mellitus. Eur J Endocrinol 2002; 147: 803-808.
- [25] Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Grantham N, Ebeling PR, Daly RM. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care 2011; 34: 1133-8.
- [26] Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: Analysis of the type of diabetes and microvascular complications. Diabetologia 1988; 31: 892-5.
- [27] Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: The Calcium and Vitamin D for Dia-

Serum 25-hydroxyvitamin D levels and diabetic retinopathy

- betes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 2011; 94: 486-94.
- [28] Robinson JG, Manson JE, Larson J, Liu S, Song Y, Howard BV, Phillips L, Shikany JM, Allison M, Curb JD, Johnson KC, Watts N. Lack of association between 25(OH) D levels and incident type 2 diabetes in older women. Diabetes Care 2011; 34: 628-34.
- [29] Chaychi L, Mackenzie T, Bilotta D, Lynch M, Cohen J, Comi R. Association of serum vitamin D level with diabetic polyneuropathy. Med Practise Rev Feb 2011; 2: 11-5.
- [30] Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T, Hiragun A. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247-250.
- [31] Suzuki A, Kotake M, Ono Y, Kato T, Oda N, Hayakawa N, Hashimoto S, Itoh M. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. Endocr J 2006; 53: 503-510.
- [32] Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha, 25-dihydroxyvitamin D (3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87: 214-220.

- [33] Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995; 36: 83-87.
- [34] Yun YW, Shin MH, Lee YH, Rhee JA, Choi JS. Arterial stiffness is associated with diabetic retinopathy in Korean type 2 diabetic patients. J Prev Med Public Health 2011; 44: 260-266.
- [35] Hamden K, Carreau S, Jamoussi K, Miladi S, Lajmi S, Aloulou D, Ayadi F, Elfeki A. 1Alpha, 25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitanimol 2009; 55: 215-222.
- [36] Al-Shabrawey M, Smith S. Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J 2010; 1: 56-72.